武田是一家致力于研發的全球制藥公司，提供以科學為基礎的創新藥品，為全球患者的健康保駕護航。武田專注于腫瘤、胃腸、中樞神經系統等疾病領域的研究，并在心血管疾病和疫苗的后期研究領域進行多項開發。武田通過內部研發以及外部合作，始終處于創新前沿地位。不斷推出的創新藥物，特別是腫瘤、消化產品，以及在新興市場的強勁表現，使武田持續增長。武田全球擁有超過30,000名員工，他們遍布于70多個國家，與醫療健康合作伙伴攜手，為全球患者帶來健康福音。有關武田的更多信息請訪問公司網站：www.takeda.com<\/a>。<\/p> \n

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
<optgroup id="kgssg"></optgroup>
<center id="kgssg"></center>
久久久亚洲欧洲日产国码二区

[1] Hou et al. Journal of Hematology & Oncology (2017) 10:137.<\/span><\/p> <\/td> \n <\/tr> \n

[2] 中華內科雜志, 2017,56(11) : 866-870. DOI: 10.3760\/cma.j.issn.0578-1426.2017.11.021<\/span><\/p> <\/td> \n <\/tr> \n

[3] 國家食品藥品監督管理總局藥品審評中心網站：http:\/\/www.cde.org.cn\/news.do?method=changePage&pageName=service&frameStr=21<\/a><\/span><\/p> <\/td> \n <\/tr> \n

[4] Takeda Presents Data from Phase 1\/2 Studies for NINLARO? (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting, June 23, 2017, https:\/\/www.takeda.com\/newsroom\/newsreleases\/2017\/phase-1-2-ninlaro-data-at-eha\/<\/a> <\/span><\/p> <\/td> \n <\/tr> \n

[5] Moreau P et al. N Engl J Med 2016;374(17):1621–34.<\/span><\/p> <\/td> \n <\/tr> \n

[6] Hou et al. Journal of Hematology & Oncology (2017) 10:137.<\/span><\/p> <\/td> \n <\/tr> \n

[7] Moreau P et al. N Engl J Med 2016;374(17):1621–34 Supplementary Appendix.<\/span><\/p> <\/td> \n <\/tr> \n

[8] Garcia-Gomez A , et al. Clin Cancer Res 2014:20:1542–54 ; Kumar SK, et al. Blood 2014 Aug 14;124(7):1047–55.<\/span><\/p> <\/td> \n <\/tr> \n

[9] 中國醫師協會血液科醫師分會, 中華醫學會血液學分會, 中國醫師協會多發性骨髓瘤專業委員會. 中國多發性骨髓瘤診治指南（2017年修訂）[J]. 中華內科雜志, 2017, 56(11): 866-870<\/span><\/p> <\/td> \n <\/tr> \n

[10] 陳文明. 《中國多發性骨髓瘤診治指南（2017年修訂）復發\/難治骨髓瘤治療部分的解讀》[J]. 中華內科雜志, 2017, 56(11): 799-800<\/span><\/p> <\/td> \n <\/tr> \n

[11] 中國醫師協會血液科醫師分會, 中華醫學會血液學分會, 中國醫師協會多發性骨髓瘤專業委員會. 中國多發性骨髓瘤診治指南（2017年修訂）[J]. 中華內科雜志, 2017, 56(11): 866-870<\/span><\/p> <\/td> \n <\/tr> \n

[12] 陳文明.多發性骨髓瘤的診斷與鑒別診斷《中國實用內科雜志》, 2006 , 26 (12) :889-891.<\/span><\/p> <\/td> \n <\/tr> \n

[13] Munshi NC & Anderson KC. Clin Cancer Res 2013;19:3337–44.<\/span><\/p> <\/td> \n <\/tr> \n

[14] 該數據源于武田中國通過研究MM發病率（0.94\/100,000）、MM中位生存時間（5年）以及MM流行病學之后，綜合計算得到<\/span><\/p> <\/td> \n <\/tr> \n

[15] Paul, G, Richardson. New developments in the management of relapsed\/refractory multiple myeloma – the role of ixazomib, Journal of Blood Medicine 2017:8 107<\/span><\/p> <\/td> \n <\/tr> \n

[16] Paul, G, Richardson. New developments in the management of relapsed\/refractory multiple myeloma – the role of ixazomib, Journal of Blood Medicine 2017:8 107<\/span><\/p> <\/td> \n <\/tr> \n

[17] Paul, G, Richardson. New developments in the management of relapsed\/refractory multiple myeloma – the role of ixazomib, Journal of Blood Medicine 2017:8 114<\/span><\/p> <\/td> \n <\/tr> \n

[18] GLOBOCAN 2012. http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_population.aspx# Accessed Nov 2016.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div>"]; $("#dvExtra").html(content_array[0]);})();
<center id="kgssg"></center>